Kidney Week

Abstract: FR-OR53

Effects of Daprodustat on Hemoglobin and Quality of Life in Patients with CKD: Results of the ASCEND-NHQ Randomized, Double-Blind, Placebo-Controlled Trial

Session Information

• Findings from Landmark Trials, Other Kidney Trials, and Observational Studies
  November 05, 2021 | Location: Simulive, Virtual Only
  Abstract Time: 04:30 PM - 06:00 PM

Category: Anemia and Iron Metabolism

• 200 Anemia and Iron Metabolism

Authors

• Johansen, Kirsten L., Hennepin Healthcare, University of Minnesota, Minneapolis, Minnesota, United States

Kirsten L. Johansen, MD, FASN

• Cobitz, Alexander Ralph, GlaxoSmithKline, Collegeville, Pennsylvania, United States

Alexander Ralph Cobitz,

• Lopes, Renato D., Duke Clinical Research Institute, Duke Health, Durham, North Carolina, United States

Renato D. Lopes,

• Singh, Ajay K., Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States

Ajay K. Singh,

• Obrador, Gregorio T., Universidad Panamericana School of Medicine, Mexico City, Mexico

Gregorio T. Obrador,

• Cizman, Borut, GlaxoSmithKline, Collegeville, Pennsylvania, United States

Borut Cizman,

• Macdougall, Iain C., King’s College Hospital, London, United Kingdom

Iain C. Macdougall,

• Okoro, Tony, GlaxoSmithKline, Collegeville, Pennsylvania, United States

Tony Okoro,

• Sprys, Michael, GlaxoSmithKline, Collegeville, Pennsylvania, United States

Michael Sprys,

• Jha, Vivekanand, George Institute for Global Health, New Delhi, India

Vivekanand Jha,

• Jolly, Shivinder Singh, Clinical Research Solutions Inc, Waterloo, Ontario, Canada

Shivinder Singh Jolly,

• Israni, Rubeen K., GlaxoSmithKline, Collegeville, Pennsylvania, United States

Rubeen K. Israni,

• Kovesdy, Csaba P., University of Tennessee Health Science Center, Memphis, Tennessee, United States

Csaba P. Kovesdy,

• Wheeler, David C., Department of Renal Medicine, University College London, London, United Kingdom

David C. Wheeler,

Background

Daprodustat (dapro) is a hypoxia-inducible factor prolyl hydroxylase inhibitor being developed for treating anemia of chronic kidney disease (CKD). In a Phase 3 trial in non-dialysis dependent (ND) CKD patients, we evaluated the effect of dapro vs placebo (PBO) on hemoglobin (Hb) and the SF-36 quality of life Vitality score (fatigue) over 28 weeks.

Methods

Adults with CKD stage 3–5, Hb 8.5–10.0 g/dL, transferrin saturation ≥15%, ferritin ≥50 ng/ml without recent rhEPO use were randomized 1:1 to dapro or PBO to maintain Hb 11–12 g/dL (NCT03409107). Primary endpoint was mean change in Hb between baseline (BL) and the evaluation period (mean over Wk 24–28). Principal secondary endpoints were 1) proportion with ≥1 g/dL increase in Hb, 2) mean change in SF-36 Vitality (fatigue) between BL and Wk 28. SF-36 Vitality responder (≥6 point increase) and blood pressure (BP) elevations were secondary endpoints. Superiority for all endpoints was tested (1-sided α=0.025).

Results

614 ND-CKD patients were randomized. BL demographic characteristics were balanced; Hb was similar (9.73 g/dL dapro, 9.71 g/dL PBO). The adjusted mean difference (AMD) in change in Hb was 1.40 g/dL (95% CI 1.23, 1.56; P<0.001). A greater proportion on dapro had a ≥1 g/dL increase in Hb from BL (77% vs 18%; P<0.001). Adjusted mean (SE) SF-36 Vitality score increased by 7.3 (1.1) points (dapro) vs 1.9 (1.2) points (PBO); AMD at Wk 28 was 5.4 (95% CI 2.2, 8.6; P<0.001, Figure). 58% on dapro vs 40% on PBO were SF-36 Vitality responders (difference 13%; 95% CI 4%, 22%). While more BP elevations occurred in dapro vs PBO (32% vs 26%, p=0.07), dapro's overall effect on BP was similar to PBO. Rates of adverse events were similar (dapro 69% vs PBO 71%).

Conclusion

In patients with ND-CKD, dapro effectively increased Hb, significantly improved the vitality score (fatigue) and was well tolerated.

Funding

• Commercial Support –